Results 41 to 50 of about 54,187 (274)

Tubulointerstitial Nephritis and Uveitis Syndrome with non Caseating Granuloma in Bone Marrow Biopsy

open access: yesActa Médica Portuguesa, 2014
The Tubulointerstitial Nephritis and Uveitis syndrome is a very rare condition, probably under-diagnosed in clinical practice. It is characterized by the combination of an interstitial nephritis and uveitis, and is an exclusion diagnosis.
Maria Fraga   +3 more
doaj   +1 more source

Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice [PDF]

open access: yes, 2019
Epoxy-fatty-acids (EpFAs), cytochrome P450 dependent arachidonic acid derivatives, have been suggested to have anti-inflammatory properties, though their effects on autoimmune diseases like systemic lupus erythematosus (SLE) have yet to be investigated ...
Dragun, Duska   +9 more
core   +2 more sources

Interstitial nephritis with moderate-to-heavy proteinuria: An unusual combination

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2012
Interstitial nephritis with proteinuria >1 g/day is uncommon and almost always the result of drug-induced ATIN with an associated minimal change glomerulonephritis (GN). Here, we present a series of five unusual cases of interstitial nephritis without GN
Biplab Ghosh   +6 more
doaj   +1 more source

Antineutrophil cytoplasmic antibody-associated vasculitis predominantly manifesting tubulointerstitial nephritis: A case report

open access: yesSAGE Open Medical Case Reports, 2023
The common histopathology of antineutrophil cytoplasmic antibody-associated vasculitis comprises pauci-immune crescentic glomerulonephritis with concomitant tubulointerstitial nephritis.
Ken Nishioka   +13 more
doaj   +1 more source

Questions about Chemokine and Chemokine Receptor Antagonism in Renal Inflammation [PDF]

open access: yes, 2010
Chemokines remain attractive therapeutic targets for modulating inflammatory diseases in all areas of medicine including acute and chronic kidney disease.
Anders, Hans-Joachim   +2 more
core   +1 more source

Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis

open access: yesKidney Medicine, 2019
Alogliptin is one of the dipeptidyl peptidase-4 inhibitors used to treat patients with type 2 diabetes. Little is known about the nephrotoxicity associated with alogliptin, such as nephrotic syndrome or interstitial nephritis.
Hisato Shima   +11 more
doaj   +1 more source

Simultaneous subacute interstitial nephritis and anticoagulant-related nephropathy related to novel oral anticoagulants use

open access: yesRenal Failure, 2022
Introduction: Interstitial nephritis related to novel oral anticoagulants was only reported in sporadic case reports and none was accompanied by anticoagulants related nephropathy (ARN).
Zhen-Ling Deng   +5 more
doaj   +1 more source

Tissue Microenvironments Define and Get Reinforced by Macrophage Phenotypes in Homeostasis or during Inflammation, Repair and Fibrosis [PDF]

open access: yes, 2012
Current macrophage phenotype classifications are based on distinct in vitro culture conditions that do not adequately mirror complex tissue environments.
Weidenbusch, Marc, Anders, Hans-Joachim
core   +1 more source

Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma

open access: yesJournal for ImmunoTherapy of Cancer, 2017
Background The anti-Programmed Death receptor 1 (anti-PD-1) antibodies nivolumab and pembrolizumab are new treatments in metastatic melanoma. Immunotherapies are best known to be responsible for thrombotic microangiopathy.
Lea Bottlaender   +5 more
doaj   +1 more source

Review of presentations at the 6th European Lupus Meeting 3-5 March 2005. [PDF]

open access: yes, 2005
The 6th European Lupus Meeting was held at the Royal College of Physicians of London and was attended by 450 delegates. The conference brought together leading speakers from Europe and North America who reviewed current knowledge and exciting new ...
Bowman, SJ   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy